GYNECOLOGIC TUMOR-MARKERS

被引：14

作者：

OLT, GJ ^{[1
]}

BERCHUCK, A ^{[1
]}

BAST, RC ^{[1
]}

机构：

[1] DUKE UNIV,MED CTR,DUKE COMPREHENSIVE CANC CTR,DEPT OBSTET & GYNECOL,BOX 3079,DURHAM,NC 27710

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 06期

关键词：

CA; 125; cancer antigen; human chorionic gonadotropin; lipid‐associated sialc acid; ovarian carcinoma‐associated antigen; peptide growth factors; radionuclide imaging; squamous cell; TA‐4;

D O I：

10.1002/ssu.2980060604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The advent of monoclonal technology has increased the potential utility of antibody‐dependent tumor marker assays in gynecologic oncology. The availability of unlimited quantities of several pure monoclonal antibodies directed against novel epitopes on tumor‐associated antigens has permitted development of highly sensitive assays for serum markers. Traditional assays for human chorionic gonadotropin (hCG), NB/70K and TA‐4 have been improved. CA 125 has provided a useful first‐generation marker for monitoring ovarian cancer and triaging patients with pelvic masses, despite limitations in sensitivity and specificity. In the next decade, the challenge is to identify new markers that will complement CA 125 in monitoring ovarian cancer and facilitate screening for occult early‐stage disease. Strategies involving multiple markers and modalities may be required. Some markers may emerge through a more fundamental knowledge of the biology of gynecologic neoplasms, including the expression of growth factors and their receptors. Finally, the application of monoclonal antibodies to immunohistochemistry and radionuclide imaging also may provide new areas of diagnostic application for monoclonal antibodies in gynecologic oncology. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company

引用

页码：305 / 313

页数：9

共 74 条

[1]

Vaitukaitis JL, Ross G, Braunstein G, Rayford PL, Gonadotropins and their submits: Basic and clinical studies, Rec Prog Hormone Res, 32, pp. 289-331, (1976)

[2]

Tyrey L, Human chorionic gonadotropin assays and their uses, Obstet Gynecol Clin North Am, 15, pp. 457-475, (1988)

[3]

Talerman A, Haije WG, Alpha‐fetoprotein and germ cell tumors: A possible role of yolk sac tumor in production of alpha‐fetoprotein, Cancer, 34, pp. 1722-1726, (1974)

[4]

Ruoslahti E, Hirai H, Alpha fetoprotein, Scand J Immunol, 8, pp. 3-26, (1978)

[5]

Kato H, Torigoe T, Radioimmucoassay for tumor antigen of human cervical squamous cell carcinoma, Cancer, 40, pp. 1621-1628, (1977)

[6]

Bast RC, Feeney M, Lazarus H, Et al., Reactivity of a monoclonal antibody with human ovarian carcinoma, J Clin Invest, 68, pp. 1331-1337, (1981)

[7]

Bast RC, Klug TL, John E, Et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med, 309, pp. 883-887, (1983)

[8]

Kabawat SE, Bast RC, Bhan AK, Et al., Tissue distribution of a coelomic‐epithelium related antigen recognized by the monoclonal antibody OC‐125, Int J Gynecol Pathol, 2, pp. 275-285, (1983)

[9]

Knauf S, Urbach GI, Identification, purification, and radioimmunoassay of NB/70K, a human ovarian tumor‐associated antigen, Cancer Res, 41, pp. 1351-1357, (1981)

[10]

Schwartz PE, Chambers SK, Chambers JT, Et al., Circulating tumor markers in the monitoring of gynecologic malignancies, Cancer, 60, pp. 353-361, (1987)

← 1 2 3 4 5 6 7 8 →